Vertex Pharmaceuticals (VRTX) Consolidated Net Income: 2009-2025
Historic Consolidated Net Income for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $1.1 billion.
- Vertex Pharmaceuticals' Consolidated Net Income rose 3.59% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 865.96%. This contributed to the annual value of -$535.6 million for FY2024, which is 114.80% down from last year.
- Vertex Pharmaceuticals' Consolidated Net Income amounted to $1.1 billion in Q3 2025, which was up 4.84% from $1.0 billion recorded in Q2 2025.
- Vertex Pharmaceuticals' 5-year Consolidated Net Income high stood at $1.1 billion for Q1 2024, and its period low was -$3.6 billion during Q2 2024.
- In the last 3 years, Vertex Pharmaceuticals' Consolidated Net Income had a median value of $968.8 million in 2023 and averaged $531.5 million.
- In the last 5 years, Vertex Pharmaceuticals' Consolidated Net Income surged by 1,109.70% in 2022 and then slumped by 492.44% in 2024.
- Vertex Pharmaceuticals' Consolidated Net Income (Quarterly) stood at $770.1 million in 2021, then climbed by 6.34% to $818.9 million in 2022, then climbed by 18.31% to $968.8 million in 2023, then decreased by 5.76% to $913.0 million in 2024, then rose by 3.59% to $1.1 billion in 2025.
- Its last three reported values are $1.1 billion in Q3 2025, $1.0 billion for Q2 2025, and $646.3 million during Q1 2025.